Scotland testing COVID-19 therapy to boost immune response early in the infection
TC BioPharm, a Scottish biotech firm, has won approval to test an experimental T-cell injection therapy to fight COVID-19 by boosting the immune system early in a coronavirus infection, the Financial Times reports. The six-month trial in Edinburgh will involve harvesting T-cells from healthy people, cultivating a large number of the cells in a lab, then injecting the donor cells into hospitalized patients. A large enough infusion could head off the infection before the patient needs to move to intensive care, and even prevent cytokine storms that ravage patients whose body mounts an overly aggressive immune response.
"We have got some evidence that if you kill the virus effectively early on, then [there] should be no reason for the host to have this overwhelming response," Dr. Nik HiraniNik Hirani at Edinburgh University's Center for Inflammation Research tells FT. TC BioPharm founder and CEO Mike Leek said the trial will focus on gamma delta T-cells, the "bully boys" of the immune system. "They circulate in surveillance mode looking for a fight and are in particular attracted to cells that are stressed either by cancer or viral infection, for which they are our first line of defense," he said.
T-cells decrease in number as people get older, so the injections might be especially helpful for elderly patients.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Chinese AI chatbot's rise slams US tech stocks
Speed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
By Peter Weber, The Week US Published
-
US port strike averted with tentative labor deal
Speed Read The strike could have shut down major ports from Texas to Maine
By Peter Weber, The Week US Published
-
Biden expected to block Japanese bid for US Steel
Speed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
By Peter Weber, The Week US Published
-
Judges block $25B Kroger-Albertsons merger
Speed Read The proposed merger between the supermarket giants was stalled when judges overseeing two separate cases blocked the deal
By Peter Weber, The Week US Published
-
Rupert Murdoch loses 'Succession' court battle
Speed Read Murdoch wanted to give full control of his empire to son Lachlan, ensuring Fox News' right-wing editorial slant
By Peter Weber, The Week US Published
-
Bitcoin surges above $100k in post-election rally
Speed Read Investors are betting that the incoming Trump administration will embrace crypto
By Peter Weber, The Week US Published
-
Enron mystery: 'sick joke' or serious revival?
Speed Read 23 years after its bankruptcy filing, the Texas energy firm has announced its resurrection
By Peter Weber, The Week US Published
-
US charges Indian tycoon with bribery, fraud
Speed Read Indian billionaire Gautam Adani has been indicted by US prosecutors for his role in a $265 million scheme to secure solar energy deals
By Peter Weber, The Week US Published